Tiffany K. Ricks

3.5k citations

21 papers · 1.8k indexed · 1 hit paper · h-index 15

Impact in

Oncology top 5%
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
Hematology top 5%
- Blood Coagulation and Thrombosis Mechanisms

Papers in

Oncology 11
- HER2/EGFR in Cancer Research 4
- Cancer Immunotherapy and Biomarkers 4
- CAR-T cell therapy research 3
- PARP inhibition in cancer therapy 2
Genetics 3
- Coagulation, Bradykinin, Polyphosphates, and Angioedema 2

Co-authors: JoAnn Trejo Richard Pazdur Puneeta Arora Shenghui Tang Breann L. Wolfe Haleh Saber Yu‐Qiang Ding Anuradha Gullapalli
Journals: Clinical Cancer Research (8 papers)Journal of Clinical Oncology (3 papers)Regulatory Toxicology and Pharmacology (2 papers)Frontiers in Oncology (1 paper)Science (1 paper)
Partner nations: United States France Japan

In The Last Decade

Tiffany K. Ricks

20 papers receiving 1.7k citations

Hit Papers

align trajectories log scale

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer 2022 · 127 citations

Peers

Countries citing papers authored by Tiffany K. Ricks

Since Specialization

Citations

This map shows the geographic impact of Tiffany K. Ricks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tiffany K. Ricks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tiffany K. Ricks more than expected).

Fields of papers citing papers by Tiffany K. Ricks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tiffany K. Ricks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tiffany K. Ricks. The network helps show where Tiffany K. Ricks may publish in the future.

Co-authors

The 25 scholars most cited alongside Tiffany K. Ricks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tiffany K. Ricks Line = papers co-authored together Tiffany K. Ricks links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer Journal of Clinical Oncology ·Mirat Shah, Ting-Yu Chen, Gwynn Ison, Mallorie H. Fiero, Hui Zhang, Xin Gao, Matthew Neilson, Kirsten B. Goldberg, Abhilasha Nair, Tiffany K. Ricks, William F. Pierce, Nicole Gormley, Marc R. Theoret, Shenghui Tang, Richard Pazdur, Paul G. Kluetz, Laleh Amiri‐Kordestani	2025	1
2	FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ Clinical Cancer Research ·Brian L. Heiss, Elaine Chang, Hee‐Koung Joeng, Mallorie H. Fiero, Lingshan Wang, Salaheldin S. Hamed, Haw-Jyh Chiu, Tiffany K. Ricks, Eun Ha Koh, Teegan A. Dellibovi-Ragheb, Min Wang, Christal Lee, William F. Pierce, John K. Leighton, Nam Atiqur Rahman, Shenghui Tang, Richard Pazdur, Laleh Amiri‐Kordestani, Paul G. Kluetz, Daniel L. Suzman	2025	2
3	US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer Journal of Clinical Oncology ·Suparna Wedam, Preeti Narayan, Haley Gittleman, Joyce Cheng, Vishal Bhatnagar, Hairat Sabit, Lauren Price, Nam Atiqur Rahman, Haw-Jyh Chiu, Nikolett M. Biel, Tiffany K. Ricks, Mallorie H. Fiero, Shenghui Tang, Christy Osgood, William F. Pierce, Richard Pazdur, Paul G. Kluetz, Laleh Amiri‐Kordestani	2025	1
4	FDA Approval Summary: Capecitabine Labeling Update under Project Renewal Clinical Cancer Research ·Sundeep Agrawal, C S Lee, William F. Pierce, Elizabeth Everhart, Adriene King-Ducre, Melanie Royce, Christy Osgood, Laleh Amiri‐Kordestani, Haw-Jyh Chiu, Tiffany K. Ricks, Lili Pan, Jeanne Fourie Zirkelbach, Rosane Charlab, Michael Pacanowski, Tamy Kim, Richard Pazdur, Paul G. Kluetz, Jennifer Gao	2024	0
5	US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations Journal of Clinical Oncology ·Asma Dilawari, James Buturla, Christy Osgood, Xin Gao, Wei Chen, Tiffany K. Ricks, Timothy J. Schaefer, Sreedevi Avasarala, Francisca Reyes Turcu, Anand Pathak, Shyam Kalavar, Vishal Bhatnagar, Justin S. Collazo, Nam Atiqur Rahman, Bronwyn D. Mixter, Shenghui Tang, Richard Pazdur, Paul G. Kluetz, Laleh Amiri‐Kordestani	2024	13
6	FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer Clinical Cancer Research ·Jennifer Gao, Christy Osgood, Zhou Feng, Erik Bloomquist, Shenghui Tang, C.J. George Chang, Tiffany K. Ricks, Sherry Hou, William F. Pierce, Donna R. Rivera, Richard Pazdur, Paul G. Kluetz, Laleh Amiri‐Kordestani	2023	3
7	FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer Clinical Cancer Research ·Jaleh Fallah, Sundeep Agrawal, Haley Gittleman, Mallorie H. Fiero, Sriram Subramaniam, Christy S. John, Wei Chen, Tiffany K. Ricks, Gang Niu, Anthony F. Fotenos, Min Wang, Kelly Chiang, William F. Pierce, Daniel L. Suzman, Shenghui Tang, Richard Pazdur, Laleh Amiri‐Kordestani, Amna Ibrahim, Paul G. Kluetz Hit paper breakdown →	2022	127
8	FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer Clinical Cancer Research ·Preeti Narayan, Christy Osgood, Harpreet Singh, Haw-Jyh Chiu, Tiffany K. Ricks, Edwin C.Y. Chow, Junshan Qiu, Pengfei Song, Jingyu Yu, Frances Namuswe, Maria Guiterrez-Lugo, Sherry Hou, William F. Pierce, Kirsten B. Goldberg, Shenghui Tang, Laleh Amiri‐Kordestani, Marc R. Theoret, Richard Pazdur, Julia A. Beaver	2021	118
9	FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma Clinical Cancer Research ·Elaine Chang, Chana Weinstock, Lijun Zhang, Rosane Charlab, Sarah E. Dorff, Yutao Gong, Vicky Hsu, Fang Li, Tiffany K. Ricks, Pengfei Song, Shenghui Tang, Peter Waldron, Jingyu Yu, Eias Zahalka, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, Amna Ibrahim, Julia A. Beaver	2020	135
10	FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer Clinical Cancer Research ·Sakar Wahby, Lola A. Fashoyin‐Aje, Christy Osgood, Joyce Cheng, Mallorie H. Fiero, Lijun Zhang, Shenghui Tang, Salaheldin S. Hamed, Pengfei Song, Rosane Charlab, Sarah E. Dorff, Tiffany K. Ricks, Kimberly Barnett-Ringgold, Jeannette Dinin, Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Laleh Amiri‐Kordestani, Julia A. Beaver	2020	114
11	An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates Regulatory Toxicology and Pharmacology ·Haleh Saber, Natalie E. Simpson, Tiffany K. Ricks, John K. Leighton	2019	61
12	An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection Regulatory Toxicology and Pharmacology ·Haleh Saber, Pedro Del Valle, Tiffany K. Ricks, John K. Leighton	2017	60
13	FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy The Oncologist ·Yang‐Min Ning, Daniel L. Suzman, V. Ellen Maher, Lijun Zhang, Shenghui Tang, Tiffany K. Ricks, Todd R. Palmby, Wentao Fu, Qi Liu, Kirsten B. Goldberg, Geoffrey Kim, Richard Pazdur	2017	112
14	FDA Approval: Blinatumomab Clinical Cancer Research ·Donna Przepiorka, Chia‐Wen Ko, Albert Deisseroth, Carolyn L. Yancey, Reyes Candau-Chacon, Haw-Jyh Chiu, Brenda J. Gehrke, Candace Gomez-Broughton, Robert C. Kane, Susan Kirshner, Nitin Mehrotra, Tiffany K. Ricks, Deborah H. Schmiel, Pengfei Song, Ping Zhao, Qing Zhou, Ann T. Farrell, Richard Pazdur	2015	261
15	Successes and Challenges of PARP Inhibitors in Cancer Therapy Frontiers in Oncology ·Tiffany K. Ricks, Haw-Jyh Chiu, Gwynn Ison, Geoffrey Kim, Amy E. McKee, Paul G. Kluetz, Richard Pazdur	2015	57
16	Immunoglobulin E plays an immunoregulatory role in lupus The Journal of Experimental Medicine ·Bárbara Dema, Nicolas Charles, Christophe Pellefigues, Tiffany K. Ricks, Ryo Suzuki, Chao Jiang, Jörg Scheffel, Sarfaraz Hasni, Victoria Hoffman, Mathieu Jablonski, Karim Sacré, Delphine Gobert, T. Papo, Éric Daugas, Steve P. Crampton, Silvia Bolland, Juan Rivera	2014	73
17	Autoreactive IgE Is Prevalent in Systemic Lupus Erythematosus and Is Associated with Increased Disease Activity and Nephritis PLoS ONE ·Bárbara Dema, Christophe Pellefigues, Sarfaraz Hasni, Nathalie Gault, Chao Jiang, Tiffany K. Ricks, Michael Bonelli, Jörg Scheffel, Karim Sacré, Mathieu Jablonski, Delphine Gobert, T. Papo, Éric Daugas, Gabor G. Illei, Nicolas Charles, Juan Rivera	2014	102
18	Kinetic Scaffolding Mediated by a Phospholipase C–β and G _q Signaling Complex Science ·Gary L. Waldo, Tiffany K. Ricks, Stephanie N. Hicks, Matthew L. Cheever, Takeharu Kawano, Kazuhito Tsuboi, Xiaoyue Wang, Craig Montell, Tohru Kozasa, John Sondek, T. Kendall Harden	2010	164
19	Phosphorylation of Protease-activated Receptor-2 Differentially Regulates Desensitization and Internalization Journal of Biological Chemistry ·Tiffany K. Ricks, JoAnn Trejo	2009	51
20	Protease-Activated Receptor-2 Is Essential for Factor VIIa and Xa–Induced Signaling, Migration, and Invasion of Breast Cancer Cells Cancer Research ·Dionne Morris, Yu‐Qiang Ding, Tiffany K. Ricks, Anuradha Gullapalli, Breann L. Wolfe, JoAnn Trejo	2006	181

About Tiffany K. Ricks

Tiffany K. Ricks is a scholar working on Oncology, Genetics, Hematology, Pulmonary and Respiratory Medicine and Immunology, having authored 21 papers that have together received 1.8k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (5 papers), HER2/EGFR in Cancer Research (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), CAR-T cell therapy research (3 papers), Bladder and Urothelial Cancer Treatments (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (2 papers) and PARP inhibition in cancer therapy (2 papers). The work is most often cited by research in Oncology (781 citations), Hematology (241 citations), Immunology (434 citations), Radiology, Nuclear Medicine and Imaging (450 citations) and Immunology and Allergy (97 citations). Tiffany K. Ricks has collaborated with scholars based in United States, France and Japan. Frequent co-authors include JoAnn Trejo, Richard Pazdur, Puneeta Arora, Shenghui Tang, Breann L. Wolfe, Haleh Saber, Yu‐Qiang Ding, Anuradha Gullapalli, John K. Leighton and Haw-Jyh Chiu. Their work appears in journals such as Clinical Cancer Research, Journal of Clinical Oncology, Regulatory Toxicology and Pharmacology, Frontiers in Oncology and Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact